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different types of portable infusion-pump devices
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Summary
Background: A variety of anticancer agents are better tolerated
and more effective if given as continuous compared to bolus
administration. Portable pump devices are needed to allow
outpatient continuous infusion. Different types of portable
pumps are available and we tested patient preference in a
randomized crossover design.
Patients and methods: Patients on continuous infusion
fluorouracil were randomly assigned to start treatment with
an elastomeric infusor (Baxter) or a mechanical, electronically
controlled pump (CADD-1®, Pharmacia) and crossed over to
the alternative model after three weeks. After exposure to both
pump types patients were asked to indicate their preferred
device.
Results: After 10 patients the study was closed because all
study participants preferred the elastomeric pump (P < 0.01).
Reasons were pump weight (100%), smaller pump size (89%),
interference with daily activities (89%), user friendliness
(56%), impact on sleep (44%), and lack of technical problems
(22%). Although the mechanical pump required more handling
time for the first two refillings, the learning curve suggested
about equal time requirement thereafter.
Conclusion: In the interest of patient comfort, the disposable
elastomeric infusor is an acceptable alternative to the more
accurate electronically controlled pumps especially for drugs
with a short half-life and a favorable toxicity profile.
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Introduction
Theoretical considerations suggest a benefit of continu-
ous infusion over bolus administration or short infusion
for various chemotherapeutic agents. Most of these
drugs are preferentially effective in specific phases of the
cell cycle. However, cancer cells of the most prevalent
solid tumors typically have a doubling time of days to
weeks and cell division is not synchronous [1,2]. On this
background, it is obvious that active drug levels and
sensitive cell cycle phase rarely coincide, if anticancer
agents are given as bolus or short infusion. However, the
chance of coincidence can be increased by extending the
infusion duration. Prolonging the duration of drug ad-
ministration may also mitigate the toxicities commonly
associated with high drug peak levels.
An absolute requirement for the practicability of
prolonged drug administration are portable pump sys-
tems to avoid hospitalization and to treat patients in an
outpatient setting. Different types of portable pump
systems are available and it is not known, which pump
characteristics are crucial for patient acceptance. Thus,
we designed a randomized crossover trial to assess the
patient preference for two fundamentally differing pump
types, which are frequently used in clinical practice. We
examined the CADD-1® device (Pharmacia, Uppsala,
Sweden), which is an electronically controlled mechan-
ical pump, and the disposable non-mechanical elasto-
meric Baxter infusor (Baxter, Volketswil, Switzerland).
Patients and methods
Consecutive outpatients on continuous infusion (200-300 mg/m2)
fluorouracil were randomized to start treatment either using the
CADD-1 or the Baxter infusor device. After three weeks of continuous
treatment, the alternative pump device was used for another three
weeks. At the end of this study period, patients were asked to fill out a
patient questionnaire evaluating preference for one of the two devices.
The nurse in charge of refilling the pump had to complete a weekly
report on pump handling and pump accuracy (nurse questionnaire).
Pump specifications
Electronically controlled portable pump (CA DD-1 * )
Size 160 x 89 x 28 mm: weight 425 g without drug. The flow rate of the
pump was kept constant at 0.5 ml per hour. Cassettes were filled with
fluorouracil (50 mg/ml) and 0.9 % saline to a total volume of 96 ml to
allow weekly intervals for changing cassettes.
Disposable nonmechunical elastomeric pump (Baxter infusor)
Size 270 x 40 x 40 mm; weight 40 g without drug. The pump provides
a constant drug flow of 0.5 ml per hour over seven days. Pumps were
filled with fluorouracil (50 mg/ml) and 0.9% saline to a total volume of
84 ml and were changed weekly.
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Figure 1 Pump handling time.
Questionnaires
Patient questionnaire
At the end of the study period, patients had to indicate their preference
for one of the two pump types and the reasons for the choice.
Nurse questionnaire
After each weekly cassette or infusor change parameters of pump
handling were evaluated and premature stop of the infusion and other
complications during the previous treatment period were assessed.
Statistical analyses
Sample size calculations
Based on the a priori hypothesis of equal preference for both pumps
and setting the clinical relevance for a difference in preference at 40%
(i.e., 90% of patients prefer one pump model), it was calculated that a
sample size of 20 patients was required to detect this difference with a
power of 80%> [3]. An interim analysis was planned after 10 evaluable
patients. Exact confidence intervals for proportions were calculated
according to Miettinen [4]. The time spent by the nurses on preparing
the infusion pumps was analyzed by repeated measures analysis of
variance using the software package Statview 4.5 for Windows.
Results
Four female and six male patients with a median age
of 61 years (range 46-81) entered this study. Patients
were treated for pancreatic (five), breast (two), rectum,
stomach, and neuroendocrine cancer of unknown pri-
mary (one each). No patient had previous experience
with portable pumps. Two additional patients starting
with the Pharmacia and one patient starting with the
Baxter pump went off treatment before crossover was
possible because of disease deterioration. All study sub-
jects had a good performance status at treatment start
without limitations for the use of a portable pump. The
study was closed after the first ten patients were crossed
over, since there was a statistically highly significant
preference for the disposable nonmechanical infusor
(P < 0.01). The reasons for this preference were lower
pump weight in 100%, smaller pump size in 89%, less
interference with daily activities in 89%, user friendliness
in 56%, less impact on sleep in 44%, and lack of
technical problems in 22% of the study participants.
Due to its elastomeric mechanism without electronic
control or external source of energy, the disposable
perfusor was less accurate than the electronically con-
trolled CADD-1® pump. Two patients experienced stop
of infusion eight and twelve hours earlier than planned
due to premature emptying of the elastic reservoir.
The time spent by the nurses to handle the pump
decreased significantly from the first to the third treat-
ment cycle (P < 0.001; Figure 1). This learning effect
appeared to be more pronounced for the technically
more demanding mechanical pump. However, this differ-
ence levelled out after two treatment cycles. This could
be partially due to the more cumbersome filling process
typical for the elastomeric pump [5], which cannot be
optimized beyond a certain degree. The time spent per
treatment cycle and the handling time was not signifi-
cantly different between both pump types.
Discussion
This study unequivocally shows, that cancer patients
prefer the disposable elastomeric infusor device over an
electronically controlled mechanical pump for the con-
tinuous infusion of fluorouracil. This choice was mainly
affected by the factors size and weight, which have a
strong impact on the visibility of the pump and patient
convenience. The importance of these 'comfort' factors
is underlined by the fact, that even the two patients, who
had to contact the hospital during the night because of
premature emptying of the elastic reservoir, still pre-
ferred this device over the mechanical pump. Thus, even
this clear evidence for inaccuracy of the flow rate had no
negative impact on patient preference.
Looking at pharmacokinetic parameters, Vokes et al.
did not detect a significant difference in the mean steady
state plasma fluorouracil levels achieved with elastomeric
compared to mechanical pumps [6]. Others have shown
that the effective flow rate of disposable pumps deviates
considerably from the intended flow rate. The pumps
typically infuse at a higher than expected rate at the
beginning of the infusion and after the first three to six
hours a steady decline of the flow rate can be observed
[5]. These pump characteristics can be potentially dan-
gerous for drugs with a narrow therapeutic window and
a long elimination half-life. However, in the case of drugs
with a short half-life such as fluorouracil, the impact
of intermittent flow changes on the steady state concen-
tration is short-lived and does not lead to drug accumu-
lation. This suggests, that the pharmacodynamic effect of
continuous infusion fluorouracil should not be affected
by transient flow irregularities.
The question of the optimal portable pump device
might lose relevance in view of the increasing availability
of oral fluorouracil prodrugs such as UFTor capecita-
bine [7, 8]. The hope is. that oral forms of fluorouracil
will be able to replace continuous infusion fluorouracil.
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However, the available clinical data suggest that contin-
uous infusion fluorouracil and oral prodrugs exhibit
differing toxicity profiles [7, 8]. Since it is well known for
fluorouracil, that the schedule of administration has a
strong pharmacodynamic impact on toxicity and effi-
cacy [9], it will have to be shown in randomized trials,
whether all continuous administration modi are inter-
changeable. It is possible, that the availability of oral
fluorouracil prodrugs adds a new dimension to the
pharmacodynamics of fluorouracil rather than replac-
ing continuous infusion.
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